Keeping the weight off after you stop: the honest version

TL;DR

• Most of the weight comes back - in the STEP 1 extension, patients regained about two-thirds of their loss within a year of stopping semaglutide, from roughly −17% on treatment to about −5.6% versus baseline.
• Tirzepatide behaved the same in kind - in SURMOUNT-4, people switched to placebo regained about 14% over the following year.
• The share still holding a meaningful (≥5%) loss fell from about 86% at end of treatment to roughly 48% a year after stopping.
• It's physiology, not willpower - resting metabolic rate falls further than your smaller size predicts, ghrelin rises and leptin falls.
• Regain comes back preferentially as fat - so repeated on-off cycling can land you at the same scale number with worse body composition.
• Obesity behaves like a chronic, relapsing condition - the long-term model, ongoing maintenance or a supervised taper, is a decision to make with a physician before you start.

MAB-reviewed and cleared for the Malaysian market (Jun 2026). Educational content, not medical advice. Compound and trial data lead; physiology is explained, not prescribed. No doses, schedules or self-directed cycling appear here - how and whether to stop, taper or maintain is a decision made with your physician.

---

Most people who stop weight-loss injections regain most of the weight, and the trials are blunt about it: a year after stopping semaglutide, patients had regained about two-thirds of what they'd lost; stopping tirzepatide brought back roughly 14%. The regain is driven by physiology, not failure - and crucially, it returns preferentially as fat. That's why how you stop, and how you protect muscle, matters as much as the loss itself. The takeaway up front: obesity behaves like a chronic condition, and the plan for keeping weight off has to be made before you start, not after you stop.

Here's what the evidence actually says.

The headline: most of it comes back

This isn't a willpower story. It's what the withdrawal trials show, repeatedly.

In the STEP 1 extension, participants who came off semaglutide regained about two-thirds of their lost weight within a year - from roughly 17% lost on treatment back to about 5.6% below baseline (Wilding et al., Diabetes, Obesity and Metabolism 2022). The share still holding a meaningful (≥5%) loss fell from about 86% at the end of treatment to roughly 48% a year after stopping. Tirzepatide looked the same in kind: in SURMOUNT-4, people switched to placebo regained about 14% over the following year, while those who stayed on kept losing.

Two molecules, the same lesson: stop, and the weight returns - not because the drug fails, but because of physiology. The mirror image is what happens when people stay on: SURMOUNT-1 has been read out to 176 weeks, and three years of tirzepatide evidence covers what that sustained result actually shows - including why an efficacy estimand makes it a treatment effect under adherence rather than a promise for anyone handed a prescription.

Why your body fights to regain

When you lose significant weight, your body treats the new lower weight as a deficit to correct, and it has powerful tools to do so - metabolic adaptation. Three parts matter:

• Resting metabolic rate falls more than your smaller size predicts. After weight loss your body burns even fewer calories at rest than someone naturally that weight. The engine idles lower.
• Appetite hormones swing toward hunger. Ghrelin (hunger) rises; leptin (satiety) falls. The drug had been overriding this; remove it and the pressure returns, often stronger.
• The body defends a set point, pushing - through appetite and metabolism - to get back to the old weight.

The medication wasn't curing this; it was holding it down. Take the lid off, and the pressure that was always underneath comes back up.

The detail that makes cycling dangerous

Here's the part rarely said, and the most important for anyone thinking "I'll just do a round, stop, and repeat." The weight you lose includes some muscle. The weight you regain is preferentially fat. Run that loop a few times and you can end up at the same number on the scale with a worse body composition - less muscle, more fat, and a lower metabolic rate that makes the next attempt harder. On-off cycling isn't a clever intermittent strategy; it can actively degrade what you're trying to improve.

This is why obesity behaves like a chronic condition

The trial authors draw the comparison themselves, and it's the right one: stopping a weight-loss drug and expecting the result to hold is like stopping a blood-pressure medication and expecting your blood pressure to stay down. The benefit was conditional on treatment - in STEP 1, the cardiometabolic improvements drifted back toward baseline once semaglutide was withdrawn, right alongside the weight. That's not a pitch to stay on a drug forever; it's honest expectation-setting. Obesity is a chronic, relapsing condition, not a one-time fix.

So what actually protects the result?

There are answers - they're just not "stop and hope."

• A realistic long-term model, chosen with a physician. Broadly two honest paths: ongoing maintenance (often at a lower dose) to keep appetite pressure managed, or a deliberate, supervised taper paired with everything below. Which fits is a clinical decision - and it's why supervision matters more at the end than the start.
• Defend your muscle - the highest-leverage thing you control. Lean mass is the metabolic floor that resists regain. Two unglamorous levers: adequate protein and resistance training, carried through the loss phase and beyond. The drug handles fat; you and your physician handle muscle.
• A sane pace and the boring fundamentals. Faster loss isn't better - it costs more muscle and triggers more rebound machinery. Sleep, protein and strength work are the scaffolding any maintenance plan stands on.
• The "bridge" idea - promising, but honest. Switching to a different agent (e.g. an amylin analogue like cagrilintide) during a break is mechanistically plausible - amylin works through a separate satiety pathway, and the CagriSema combination reached about −20.4% in a phase 3 trial (REDEFINE 1, NEJM 2025). But using it specifically as a bridge during a break is reasonable and not yet trial-proven. It's a supervised option to discuss, never a self-directed cycle.

The bottom line - and where to start

If someone promises a course of injections will fix your weight permanently, they're misinformed or selling something. The trials are clear: stop, and most of the weight comes back, preferentially as fat. That's not a reason to avoid these drugs - they're among the most effective tools we've had for obesity - it's a reason to go in with the right plan: treat the condition as chronic, protect your muscle, and decide the long-term model with a physician before you start. The weight loss is the easy, visible part. Keeping it is the real work - and the part worth choosing a supervised programme for.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore semaglutide.

Related reading

• Losing fat, not muscle, on a GLP-1 - protecting muscle is central to maintenance
• Why your weight loss stalls on a GLP-1 - plateaus and the same metabolic adaptation
• Mounjaro vs Wegovy vs Ozempic: the honest comparison - choosing the molecule with your physician
• Three years of tirzepatide evidence - what the longest completed trial does and doesn't establish

---

Educational content, not medical advice. Decisions about starting, maintaining, tapering or stopping any weight-loss medication - and any combination or "bridge" approach - must be made with a supervising physician. Trial figures describe study populations; individual results vary. Claims for the Malaysian market were reviewed and cleared by MAB (Jun 2026).

Primary references

• Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022 (PMID 35441470). (regained ~two-thirds; net −5.6% at week 120)
• Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA 2024. (~14% regained after withdrawal)
• Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989–1002.
• CagriSema (cagrilintide–semaglutide), REDEFINE 1. N Engl J Med. 2025. (−20.4%; amylin + GLP-1 combination context)